Global Asthma & COPD Drugs Market Analysis

The Global Asthma & COPD Drugs Market size stood at around xx Bn in 2023 and is projected to reach US $xx Bn by 2033, exhibiting a CAGR of xx% during the forecast period.

The Global Asthma & COPD Drugs Market Analysis Executive Summary

Asthma and chronic obstructive pulmonary disease (COPD) are both lung conditions that cause airway inflammation, making breathing difficult. Asthma usually flares up in response to allergens like pollen or mold, or due to physical exertion. In contrast, COPD encompasses several lung diseases, including emphysema and chronic bronchitis. Emphysema involves damage to the lung’s tiny air sacs (alveoli), while chronic bronchitis is characterized by inflammation of the airways (bronchial tubes). Smoking is the primary cause of COPD. Asthma symptoms can vary and may disappear for extended periods, whereas COPD symptoms are persistent and tend to worsen over time, despite treatment. 

The global increase in COPD and asthma caused by industrialization, pollution, and change of lifestyles requires improved medical devices and drugs. Technological developments including nebulizers and smart inhalers are enhancing treatment and education, yet high costs, poor reimbursement, and regulatory constraints are a challenge. Increased growth within the market is likely to result from improvements in drug delivery and monitoring services coupled with higher demand in the Asia-Pacific region because of high smoking rates and better health literacy. High costs, reimbursement issues, safety concerns, and environmental impacts may act as threats to growth. Solving these calls for affordable, efficient and environmentally sustainable products and services. Policies and regulatory authorities will continue to shape the market and access to products through reimbursement and value-based care models.    

Global Asthma & COPD Drugs Market Dynamics

Market Growth Drivers

A number of people suffering from COPD and asthma is on the rise in the global arena boosted by factors such as urbanization, pollution, and lifestyle changes making it necessary to invest in improved medical equipment and medication. Advancements like complex nebulizers and smart inhalers increase the usage rate and efficacy of treatment, auguring well for the market. Efforts to raise awareness of patients with respiratory conditions are also driving the adoption of COPD treatments and diagnosis of asthma. However, there are still barriers to growth such as high treatment costs, lack of reimbursement, and restrictive regulatory measures leveled against manufacturing companies such as small and medium-sized enterprises. These challenges effectively become the barriers that create the possibility of putting into place the more effective solutions. 

Opportunity

The market for COPD and asthma equipment, including smart inhalers and Advanced nebulizers, is expected to grow based on progressing technologies in COPD and asthma drug delivery and monitoring. Global prevalence and incidence of COPD and asthma are rising due to urbanization, pollution, and changes in lifestyles, which are boosting demand for these tools. Smoking rates are on the rise, coupled with improvement in overall healthcare knowledge in regions like Asia-Pacific where market growth is expected to explode from growing incomes. Besides, the steadily increasing need for over-the-counter remedies and long-term management of conditions and disorders together with increased awareness campaigns are some of the factors that are promoting the market’s growth. 

Market Restraints

Increased expense concerning the products used in the management of asthma and COPD contributes to poor utilization among those affected, especially in developing countries. This is worsened by limited reimbursement and healthcare resources as has been mentioned earlier. Manufacturing or safety issues that lead to the recall of these items may lead to reduced sales because customers are hesitant to buy these foods. Other non-pharmacological management options and concerns over use of propellants in the devices can also affect demand. Hence, one of the crucial strategies for addressing these issues is the creation of affordable, efficient, and sustainable substitutes. 

Competitive Landscape for Asthma & COPD Drugs Market in Global

Key Players

• GlaxoSmithKline Plc
• AstraZeneca Plc
• Novartis AG
• Boehringer Ingelheim GmbH
• Merck & Co Inc
• F. Hoffmann-La Roche Ltd

Recent Developments:

July 2024, Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD 

July 2023, The first generic equivalent of AstraZeneca's Symbicort, Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, was introduced by Viatris.

October 2021, Glenmark Pharmaceuticals has launched the Tavulus dry powder inhaler (DPI) in Spain for the treatment of chronic obstructive pulmonary disease (COPD)

June 2021, ChiesiFarmaceuticiSpA has begun the PILASTER study to assess the efficacy and safety of two doses of CHF6001 (Tanimilast) as an add-on to maintenance triple therapy in COPD patients.

Mergers and Acquisitions:

2021, AstraZeneca's $39 billion acquisition of Alexion Pharmaceuticals has bolstered its pipeline in rare diseases and immunology, including treatments for asthma and COPD. 

Healthcare Policies and Regulatory Landscape for Asthma & COPD Drugs Market in Global

Policy changes and Reimbursement scenario

Governments are coming up with policies and campaigns to discourage smoking and these will have an effect on the COPD and asthma markets due to the disease incidence reduction. Bureaus such as the FDA and EMA play a role in determining the rate of new drugs approval whereby policy changes have the potential to increase the market entry rates as well as new innovative products. Government legislation may include some environmental standards, for example, in respect to propellants used in inhalers. Increased coverage for reimbursement trends and the rise of value-based care can further improve patient access and market growth. However, this pressure on the producers to keep their prices as reasonable as possible might slow growth of the market due to reduced gross and competition.